The revenue increase was driven in part by surging direct sales of the firm's diagnostic test cartridges and instruments in Europe, the Middle East, and Asia.
Revenues fell as an increase in sales of test cartridges for its Unyvero molecular diagnostic instrument was offset by a decline in system and service sales.
The company said it will use the proceeds for the US commercial launch of its Unyvero molecular diagnostic platform, among other things.
The test cartridge runs on the company's Unyvero platform and covers 103 diagnostic targets for various pathogens and markers of antibiotic resistance.
The firm also received approval from the Singapore Health Sciences Authority to market the Unyvero blood culture cartridges.
The PCR-based cartridge is designed to detect 21 pneumonia pathogens and 19 genetic markers of antibiotic resistance, and runs on the company's Unyvero system.
The company also announced that its Ares Genetics subsidiary has been awarded a €1.6 million grant to develop antibiotic resistance technologies.
The firms plan to integrate Curetis' Unyvero sample prep system and MGI's NGS to create a microbial pathogens and antibiotic resistance detection workflow.
The company attributed the drop in revenue to delays in some placements of its Unyvero molecular diagnostic system.
Curetis and BGI subsidiary MGI Tech plan to develop NGS-based diagnostics for microbial infections on the MGISeq instrument for the Chinese market.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.